Plus therapeutics to present rhenium-186 nanoliposome data at the american society for radiation oncology (astro) 2021 annual meeting

Austin, texas, sept. 23, 2021 (globe newswire) -- plus therapeutics, inc. (nasdaq: pstv) (the “company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data regarding its rhenium-186 nanoliposome (186rnl) investigational radiotherapeutic for recurrent glioblastoma (gbm) at the american society for radiation oncology (astro) 2021 annual meeting being held in person october 24-27, 2021 in chicago, illinois.
pstv Ratings Summary
pstv Quant Ranking